New Data Demonstrates Disease Control for Inflammatory Bowel Disease Patients with SKYRIZI® and RINVOQ®

AbbVie has announced new data for its treatments SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib), showcasing disease control for patients living with inflammatory bowel disease (IBD). The findings include new Phase 3 AFFIRM results for SKYRIZI in advanced therapy-naïve Crohn's disease patients and real-world evidence supporting RINVOQ in advanced Crohn's disease.